

# Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 21, 2025

## SU.86.86

RRID:CVCL\_3881

Type: Cell Line

---

### Proper Citation

(RRID:CVCL\_3881)

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_3881](https://web.expasy.org/cellosaurus/CVCL_3881)

**Proper Citation:** (RRID:CVCL\_3881)

**Sex:** Female

**Defining Citation:** [PMID:3264833](#), [PMID:10027410](#), [PMID:11115575](#), [PMID:15126341](#), [PMID:15688027](#), [PMID:16912165](#), [PMID:18380791](#), [PMID:20037478](#), [PMID:20418756](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

**Comments:** Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: miRNA expression profiling., Omics: Metabolome analysis., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Omics: Array-based CGH., Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Name:** SU.86.86

**Synonyms:** Su.86.86, SU 86.86, SU-86-86, Su-86-86, SU86.86, SU86-86, SU86\_86, Su86\_86, SU8686, SU.86

**Cross References:** BTO:BTO\_0001904, CLO:CLO\_0009150, EFO:EFO\_0006494,

ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1837, BioGRID\_ORCS\_Cell\_line:196, BioSample:SAMN03472014, BioSample:SAMN10987701, cancercellines:CVCL\_3881, Cell\_Model\_Passport:SIDM01188, CGH-DB:183-1, CGH-DB:9282-4, ChEMBL-Cells:ChEMBL4630607, ChEMBL-Targets:ChEMBL4630707, Cosmic:707252, Cosmic:868244, Cosmic:873003, Cosmic:913314, Cosmic:922250, Cosmic:923172, Cosmic:932522, Cosmic:949237, Cosmic:1006362, Cosmic:1066203, Cosmic:1122349, Cosmic:1218879, Cosmic:1358486, Cosmic:1518237, Cosmic:1644315, Cosmic:1995645, Cosmic:2434090, Cosmic-CLP:1240218, DepMap:ACH-000114, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240218, GEO:GSM206545, GEO:GSM621901, GEO:GSM784693, GEO:GSM887650, GEO:GSM888742, GEO:GSM1024414, GEO:GSM1374903, GEO:GSM1435693, GEO:GSM1435694, GEO:GSM1435695, GEO:GSM1670481, IARC\_TP53:2860, IZSLER:BS TCL 180, LiGeA:CCLE\_401, LINCS\_LDP:LCL-1747, PharmacDB:SU\_86\_86\_1506\_2019, PRIDE:PXD003198, PRIDE:PXD030304, Progenetix:CVCL\_3881, PubChem\_Cell\_line:CVCL\_3881, SKY/M-FISH/CGH:2000, Wikidata:Q54970749

**ID:** CVCL\_3881

**Record Creation Time:** 20250131T202727+0000

**Record Last Update:** 20250131T204705+0000

---

## Ratings and Alerts

No rating or validation information has been found for SU.86.86.

No alerts have been found for SU.86.86.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 19 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [FDI Lab - SciCrunch.org](#).

Zhang S, et al. (2024) Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. Cell death discovery, 10(1), 124.

Moreno P, et al. (2024) ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. bioRxiv : the preprint server for biology.

Ohara Y, et al. (2024) LMO3 is a suppressor of the basal-like/squamous subtype and

reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism. Carcinogenesis.

Tsao HW, et al. (2024) Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. *Immunity*, 57(12), 2863.

Ohara Y, et al. (2024) ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer. *International journal of cancer*, 155(3), 569.

Sonnemann HM, et al. (2024) Placental co-transcriptional activator Vestigial-like 1 (VGLL1) drives tumorigenesis via increasing transcription of proliferation and invasion genes. *Frontiers in oncology*, 14, 1403052.

Tao J, et al. (2024) CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. *Journal of experimental & clinical cancer research : CR*, 43(1), 277.

Ohara Y, et al. (2023) SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer. *Cell reports*, 42(12), 113434.

Paul MC, et al. (2023) Non-canonical functions of SNAIL drive context-specific cancer progression. *Nature communications*, 14(1), 1201.

Zhang J, et al. (2023) Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer. *Cancers*, 15(19).

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. *Nature communications*, 14(1), 3742.

Hunihan L, et al. (2022) RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(14), 3091.

Kaur G, et al. (2021) Complex Tumor Spheroids, a Tissue-Mimicking Tumor Model, for Drug Discovery and Precision Medicine. *SLAS discovery : advancing life sciences R & D*, 26(10), 1298.

Yang G, et al. (2021) CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma. *Cellular oncology (Dordrecht)*, 44(2), 345.

Joshi S, et al. (2021) Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer. *Communications biology*, 4(1), 1333.

Greenstein AE, et al. (2021) Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells. *Oncotarget*, 12(13), 1243.

Yan P, et al. (2020) Molecular Stressors Engender Protein Connectivity Dysfunction through

Aberrant N-Glycosylation of a Chaperone. Cell reports, 31(13), 107840.

Sulahian R, et al. (2019) Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell reports, 29(1), 118.

Nagarajan A, et al. (2017) Paraoxonase 2 Facilitates Pancreatic Cancer Growth and Metastasis by Stimulating GLUT1-Mediated Glucose Transport. Molecular cell, 67(4), 685.